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Abstract
Recent findings suggest that mammalian cells can use small non-coding RNAs (ncRNA) to regulate
physiological viral infections. Here, we comment on several lines of evidence that support this
concept. We discuss how viruses may in turn protect, suppress, evade, modulate, or adapt to the
host cell's ncRNA regulatory schema.
Small RNAs: interference and activation?
Plant and animal genomes have thousands of genes that
encode non-protein-coding (nc) RNAs. While recent
attention has focused significantly on small interfering
RNAs (siRNAs) and micro RNAs (miRNAs), ncRNAs also
include rRNA, tRNA, small nuclear (sn) RNA, small nucle-
olar (sno) RNAs, and some of the lesser-known RNAs
such as vault RNAs, Y RNAs, rasi-RNAs and piRNAs
[reviewed in [1]]. It is now recognized that only 2% of the
human genome encodes for protein-coding RNAs while
60 to 70% of our DNA is transcribed into ncRNAs [2,3].
Hence, despite accumulating research on siRNA, miRNA
and piRNA, we are likely at the tip of the iceberg in our
understanding about functions and regulatory roles
served by ncRNAs in cellular metabolism, pathogenesis
and host-pathogen interaction.
A key biological process served by small ncRNAs is a phe-
nomenon termed RNA interference (RNAi). Recent
reviews have reprised the discovery of RNAi and summa-
rized the current state of knowledge about this process
[4,5]. In brief, a central tenet of RNAi posits that small
guide RNAs recruit, in a sequence-complementary man-
ner, a multi-protein complex composed in part of RNA-
binding proteins to RNA targets. This large multi-protein
RNAi complex has been shown to include members of the
Argonaute ribonuclease III protein family; and depending
on biological context, the complex has been found to
effect post-transcriptional gene silencing (PTGS), tran-
scriptional gene silencing (TGS), and/or co-transcrip-
tional gene silencing (CTGS) (Fig. 1, top).
Conventional wisdom suggests that biological processes
are balanced by two principles, yin and yang, which
oppose one another in their actions to confer equilibrium.
For example, the cell-proliferative effects of oncogenes are
countered by commensurate provocations of cellular
senescence and apoptosis [6-8]. Moreover, frequently,
potent transcriptional activators are also equally strong
repressors [9,10]. Indeed, recent developments raise that
the yin (negative) of RNAi may be shadowed by a yang
(positive). Thus, some cellular [11-14] and viral [15] stud-
ies now suggest that a rarely-glimpsed face of "RNAi" may
visualize activation rather than repression. Verily, RNA
sequence-mediated positive regulation could exist more
prevalently than currently acknowledged since, in princi-
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ple, there is no reason why other RNA-binding proteins
different from Argonaute-related members cannot be sim-
ilarly tagged and guided by ncRNAs (Figure 1, bottom).
Mammalian cells, viruses and small ncRNAs
Biological studies on mammalian viruses have illumi-
nated aspects of gene regulation by small non-coding
RNAs and their RNA-binding proteins. Early results from
the HIV-1 TAR RNA and its binding protein Tat framed a
platform for how a small non-coding RNA and a viral
RNA-binding protein cooperate to up modulate gene
expression [16,17]. Indeed, although unrecognized at the
time, the first human cellular protein identified to bind
TAR RNA, TRBP [18,19] presaged a clue to the mechanis-
tic process of RNAi. Hence, fourteen years after the initial
characterization of its binding to TAR, TRBP was revealed
as a crucial component of the mammalian miRNA
processing machinery [20-22]. Consistent with TRBP's
role in miRNA-processing, a recent report demonstrated
that TAR RNA in human cells is engaged by TRBP and
processed by the RNAse III Dicer protein into a miRNA
guide [23].
The above sequence of events not withstanding and
although the RNAi machinery is preserved intact in mam-
malian cells and mammalian RNAi machinery can be
instructed to target invading viruses in therapeutic set-
tings, there is a school of thought that mammals do not
use ncRNA/RNAi to regulate viral infections [24]. This
view is partly rationalized by the argument that mammals
have a surfeit of other means to defeat effectively viral
pathologies; thus an intact mammalian RNAi machinery
is not needed, and cells have extinguished this mecha-
nism as it applies to viral infection [24]. Confoundingly,
that annually 3 million human deaths arise from HIV-
infection alone [25] and ~20% of all human cancers are
caused by viral infections [26] indicate that mammalian
defenses are not nearly so replete that effective antiviral
pathway(s) should become extinct.
Recent experimental findings are, in fact, consistent with
physiological use by mammalian cells of small ncRNA/
RNAi to regulate viruses. First, three studies have con-
verged to illustrate that small ncRNAs (siRNAs and piR-
NAs) are used in human and mouse cells to suppress the
replication of endogenous retroviruses (i.e. retrotrans-
posons) [27-29]. Second, bioinformatics and experimen-
tal results persuasively imply that mammalian viruses
including HIV-1 are targeted by discrete human miRNAs
[30-34]. Third, repression of mammalian Dicer enzyme
was found to up regulate cellular replication of HIV-1 and
vesicular stomatitis virus (VSV) [35-37]. One straightfor-
ward interpretation of the latter finding, which does not
exclude others, is that the unrepressed mammalian Dicer-
RNAi pathway normally acts to moderate HIV-1 and VSV
replication. Finally, a KSHV viral miRNA (miR-K12-11)
was identified as a viral orthologue of human miR-155
[38]. To the extent that miR-K12-11 targets KSHV- and cel-
lular- sequences, then cellular miR-155 can be reasoned to
act upon the same KSHV-sequence regulated by miR-K12-
11. Indeed, pending the clarification of additional details,
extant observations are consistent with the employment
of ncRNAs by mammalian viruses to regulate viral func-
tions, by mammalian cells to regulate cellular functions,
by mammalian viruses to regulate cellular functions, and
by mammalian cells to regulate viral functions (Figure 2).
Viral responses?
If cells restrict viruses with non-coding RNAs, do viruses
respond with countermeasures? In principle, viral counter
stratagems could include a) protection from restriction, b)
suppression of restriction; c) evasion from restriction; d)
modulation of restriction profiles, and e) adaptation to
restriction.
Protection
Experimental findings suggest the existence for mamma-
lian viruses of each of the above five mechanisms. Regard-
ing protection, Berkhout and colleagues have reported
that RNA genomes can be physiologically shielded from
RNAi in a privileged format [39]. Nevertheless, this pro-
tection cannot prevail for unpackaged viral genomes or
for transcribed viral mRNAs. Accordingly, viral mecha-
nism(s) for RNAi-blunting or -suppression might be
required in unprotected settings.
Schematic representations of positive and negative regulation  mediated through ncRNA-guide sequences Figure 1
Schematic representations of positive and negative regulation 
mediated through ncRNA-guide sequences. RBPx is to illus-
trate a negative multi-RNA-binding protein regulatory com-
plex that is tagged by a ncRNA-guide and recruited based on 
sequence-complementarity to target; while RBPy is to repre-
sent a theoretical positive multi-RNA-binding protein com-
plex. PTGS, post-transcriptional gene silencing; TGS, 
transcriptional gene silencing; CTGS, co-transcriptional gene 
silencing. Currently, while there are many examples of RBPx, 
there is yet little published evidence for RBPy.Retrovirology 2007, 4:74 http://www.retrovirology.com/content/4/1/74
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Suppression
Indeed, viruses appear to possess at least two means to
suppress RNAi. First, virus-encoded RNA-binding proteins
partly serve an RNAi-neutralization function. This mecha-
nism while well-accepted for viruses in lower eukaryotic
cells [40] has been debated for mammals. Relevant to
HIV-1, two studies have attributed RNAi-suppressive
activity to the arginine-rich RNA-binding Tat protein
[41,42], while a third study has questioned this concept
[43]. Interestingly, the interpreted absence of Tat-associ-
ated RNAi-suppression in the latter study is complicated
by high non-specific transcriptional activation of TAR-less
cellular promoters by Tat, a finding inconsistent with the
known specificity of Tat for TAR-RNA [44-46]. Second, in
a separate way, mammalian viruses suppress RNAi by syn-
thesizing small viral RNA decoys that competitively
occupy RNAi machinery, preventing the processing of
authentic RNAi precursors [47-49]. Because stringent glo-
bal suppression of RNAi is likely incompatible with the
viability of mammalian cells [50], virus-mediated RNAi-
suppression is likely to be physiologically modest and
localized in scope. This could explain difficulties in visu-
alizing suppressive activities in non-viral transfection-
based over expression assays.
Evasion
If protection or suppression fails, viruses can evade
sequence-complementarity-driven RNAi through muta-
tions. Highly mutable viruses like HIV-1 are proficient at
sequence- or secondary structure- changes [51,52]. Exper-
imental findings of rapid HIV-1 mutation under artificial
siRNA-pressure do not, however, address whether ncRNA-
based selection against HIV-1 exists physiologically in
human cells. Here, supportive data are difficult to accu-
mulate because by definition effective evasion (from e.g.
miRNAs) means loss of evidence for base complementa-
rity in viral genomes (to miRNAs). Hence, viruses with no
human miRNA-footprints may actually be viruses that
experience the strongest miRNA- selection. In a setting
where an absence of finding may be indicative of evasion,
how might one collect clues? An answer may reside with
searching for human miRNA-target sites in viral genomes
containing tell-tale mismatches. For example, rare HIV-1
sequence which appears to be targeted by human miRNAs
(see Figure 3, an HIV pNL4-3 "target" of human miR-326)
carries a hallmark change near the miR-seed sequence
partly consistent with APOBEC (deoxycytidine deami-
nase) -mediated G to A mutation. In this example, one
could change the putatively escaped "A" back to a "G" in
the HIV genome, and test if the original "non-escaped"
HIV-1 is subject to vigorous miR-326-selection. Such
experimental design could provide findings supportive of
a hypothesis that current HIV-1 RNA sequences are con-
tinually shaped and maintained by ambient RNAi pres-
sure.
Modulation and adaptation
Failing protection, suppression, and evasion from miR-
NAs, viruses may modulate the cell's miRNA expression
profile [35,53], or viruses may ultimately adapt miRNA-
restriction to benefit viral replication [15]. In the former
setting, RNA-binding proteins such as Tat which act in the
nucleus as well as affect cytoplasmic events via binding to
tubulin [54-56] could significantly remodel cellular
miRNA profiles [53]. In the latter scenario, human hepa-
titis C virus is currently the one rare example compatible
with an adaptation paradigm [15]. As we learn more
about miRNA -targets and -biology, better understandings
of setting-specific negative versus positive modulations
and adaptations will likely emerge.
Perspectives and Predictions
We have outlined in brief two views on virus- cell ncRNA
interaction in mammals. The first view embraces a null
hypothesis --- virus-cell ncRNA interactions exist in lower
eukaryotes but not physiologically in mammals [24].
While this view may be correct, several lines of evidence
Four different ways for viral (v) ncRNAs and cellular (c)  ncRNAs to interact in mammalian cells Figure 2
Four different ways for viral (v) ncRNAs and cellular 
(c) ncRNAs to interact in mammalian cells. A) shows 
vncRNA regulating virus; B) shows cncRNA regulating cells; 
C) shows vncRNA regulating cells; D) illustrates cncRNA 
regulating virus. Experimental evidence compatible with each 
of these four pathways exists in the published literature.Retrovirology 2007, 4:74 http://www.retrovirology.com/content/4/1/74
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discussed here point against its limitations. A second view
is that the RNAi machinery exists in mammalian cells not
just for artificial siRNA-exploits but as a physiological
mechanism used by cells and viruses to regulate viral and
cellular functions (Figure 2). Subsumed within this view
is the thesis that RNAi is a part of the armamentarium
used by mammalian cells to regulate, perhaps positively
and negatively in context-specific fashion, the replication
of endogenous and exogenous viruses. We anticipate that
more time and further investigation will be needed to val-
idate the accuracy of the one or the other view point.
If small ncRNAs are used in mammalian cells to regulate
cellular and viral functions, then one could venture sev-
eral predictions. First, many more (cellular and viral)
RNA-binding proteins that adapt small RNAs to mediate
both negative and positive gene regulation will be
revealed. Second, mammalian viruses will be shown to
encode a variety of ncRNAs that have regulatory roles.
Some future examples might mirror the HTLV-1 regula-
tory HBZ ncRNA [57]; others may emerge from the
processing of antisense HIV-1 and HTLV-1 transcripts [58-
60]; and even others may behave like TAR or RRE. Third,
additional viral RNA-binding proteins (perhaps Rev and
Rex) will be shown to have setting-specific RNAi- modu-
latory properties, and many viruses will be found to exten-
sively reshape cellular miRNA expression profiles.
Since its first description a relatively short period of time
ago, 9868 papers have already been published on RNAi
(data from Pubmed search using the term, RNAi). An
additional prediction (which will almost certainly be cor-
rect) is that RNA-guided gene regulation will continue to
hold many exciting and unexpected scientific findings
which will be published profusely in the coming years.
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